Refine by
Liver Toxicity Suppliers & Manufacturers
5 companies found
based inDiepenbeek, BELGIUM
Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug ...
In vitro and in vivo methods to provide a study setup that thoroughly determines safety and efficacy. ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder ...
based inLancaster, CALIFORNIA (USA)
Simulations Plus provides cutting-edge software solutions and consulting services designed to enhance drug discovery, clinical development, and regulatory submission processes. With over 25 years of experience, the company has established itself as ...
DILIsym is a sophisticated quantitative systems toxicology (QST) software designed to predict and elucidate drug-induced liver injury (DILI). This tool utilizes a middle-out, multi-scale modeling approach to simulate the complex ...
based inMississauga, ONTARIO (CANADA)
Award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The company is targeting anxiety, depression, ...
Mentanine®, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous ...
based inParis, FRANCE
Curadigm is an early-stage company focused on shifting the paradigm of therapeutic clearance, bioavailability, and efficacy to improve treatment outcomes for millions of patients. Curadigm was spun-off from Nanobiotix, a late-stage clinical company, ...
Curadigm’s technology was developed to address a critical challenge facing intravenously administered therapeutics: How can you efficiently deliver a drug to your tissue of interest without rapid clearance? To address this, we ...